One of the investors in the undisclosed licencing deal is fast-growing Chinese tea firm Ningji.

The US pharmaceutical giant will pay $650m upfront to support 12 cancer medicine programmes with HKEX-listed Innovent; the collaboration includes co-commercialisation rights in the US and Europe.

Industrial activity remained a “consistent bright spot" throughout 2025 amid 5% GDP growth; there are consistent deflationary pressures.

Proceeds from the one-year zero coupon guaranteed bonds will be used to support the non-ferrous metal company’s overseas business.

Hong Kong's finance secretary Paul Chan said the deal will "attract more cross-boundary Rmb financing and trading activities to Hong Kong".

Three brokers, including Hong Kong’s largest online brokerage Futu, have been heavily penalised by Chinese regulators, in an effort to clean up market misconduct and to curb illegal outflows.

Rather than relying solely on exports, Chinese companies are gradually integrating into Europe’s industrial fabric, argues Collabrium Partners' Adam Zhang Yu.

The HKEX listed aluminium giant will use the money to stockpile bauxite, refinance debt, to invest in overseas projects, share repurchases and for general corporate purposes; it also made a concurrent share repurchase.

From May 1, Cindy Lo will become regional managing partner and Roger Lui will become senior partner, both for Greater China.

The Galaxy Orientis fund has raised $520m out of a $1bn target from China Investment Corporation, Indonesia Investment Authority and State Oil Fund of the Republic of Azerbaijan. The PE fund is eyeing investments across the Asean-China corridor.